03 May Caeregen Therapeutics Announces Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Data presented on promising activity of Noregen™, first potential regenerative therapy for retinal diseasesFollows 1Q2022 U.S. FDA and EU EMA Orphan Drug Designation (ODD) for Noregen™ in Familial Exudative Vitreoretinopathy (FEVR) May 3, 2022, Denver, CO and Rochester, MI – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company...